Find research datasets worth reusing

Safety and Efficacy Study to Evaluate Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis

ClinicalTrials.gov study NCT01732770. IPD Sharing: Not stated. Countries: 7. Publications: 3.

A Study to Compare SB16 (Proposed Denosumab Biosimilar) to Prolia® in Postmenopausal Women With Osteoporosis

ClinicalTrials.gov study NCT04664959. IPD Sharing: Not stated. Countries: 1. Publications: 1.

Denosumab for Prevention of Osteoporosis in Renal Transplant Recipients

ClinicalTrials.gov study NCT01377467. IPD Sharing: NO. Countries: 1. Publications: 2.

Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption

ClinicalTrials.gov study NCT01750086. IPD Sharing: Not stated. Countries: 1. Publications: 6.

Study of Denosumab in Subjects With Giant Cell Tumor of Bone

ClinicalTrials.gov study NCT00680992. IPD Sharing: Not stated. Countries: 12. Publications: 9.

Denosumab Fracture Intervention Randomized Placebo Controlled Trial in Japanese Patients With Osteoporosis

ClinicalTrials.gov study NCT00680953. IPD Sharing: Not stated. Countries: 1. Publications: 3.

Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy

ClinicalTrials.gov study NCT02129699. IPD Sharing: NO. Countries: 11. Publications: 5.

Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

ClinicalTrials.gov study NCT00896454. IPD Sharing: Not stated. Countries: 5. Publications: 1.

controlledIPD-YESFeb 2026View details →

Safety and Efficiency of Denosumab in Pediatric Subjects With Glucocorticoid-induced Osteoporosis

ClinicalTrials.gov study NCT03164928. IPD Sharing: YES. Countries: 13. Publications: 0.

Efficacy and Safety of Denosumab Compared With Risedronate in Individuals Taking Glucocorticoids

ClinicalTrials.gov study NCT01575873. IPD Sharing: Not stated. Countries: 16. Publications: 2.

opencc-by-4.0Oct 2022View details →

zenodo32/100

Efficacy of switching from teriparatide to zoledronic acid or denosumab on bone mineral density and bone markers in patients with severe fractured osteoporosis: a real-life study

Abstract Purpose: Osteoporosis is characterized by a loss of bone mass, increased bone fragility and susceptibility to fracture. Sequential treatment with bisphosphonates or denosumab (Dmab) after teriparatide (TPT) discontinuation may represent a valid treatment option, but the optimal sequential treatment strategy is unknown. Methods: This retrospective study enrolled 56 osteopenic/osteoporotic patients with fragility fractures who received 24 months of treatment with TPT followed by 24 months of treatment with zoledronic acid (ZOL) (TPT+ZOL) or Dmab (TPT+Dmab). Clinical features, incident fractures, bone mineral density (BMD) measurements, and bone marker profiles were characterized. Ordinary one-way ANOVA adjusted for multiple testing analyzed the difference between median T-scores at baseline, after 24 months of TPT, and after 2 doses of ZOL or at least 3 doses of Dmab when variables failed the normality test. Results: Twenty-three patients received TPT+ZOL (19 females, 4 males; median [IR] age, 74.3 [66.9, 78.6] years) and 33 patients received TPT+Dmab (31 females, 2 males; mean±SD age, 66.6±11.3 years). Mean lumbar and hip T-scores were significantly higher after sequential treatment with both TPT+ZOL and TPT+Dmab (all p<0.05 vs baseline). In particular, the mean lumbar T-score increased in about 80% of patients by 8.5±58% after ZOL, while after Dmab, the mean lumbar T-score was -9.6±36%. Mean±SD femur neck and hip T-scores increased by 12±13% and 9±31%, respectively, after treatment with ZOL, while the change in femur neck and hip T-scores after Dmab were 5±41% and 27±36%, respectively, No significant between-group differences were identified. Fragility fractures occurred in 3 (13%) patients treated with TPT+ZOL and in 5 (15%) patients treated with TPT+Dmab. Conclusion: Sequential therapy with TPT+ZOL increased bone mineralization at the lumbar level and stabilized bone mineralization at the femoral level. Both ZOL and Dmab are effective sequential treatments after TPT.

Denosumab and Osteoporotic Vertebral Compression Fracture

ClinicalTrials.gov study NCT05058443. IPD Sharing: NO. Countries: 1. Publications: 3.

Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density

ClinicalTrials.gov study NCT00043186. IPD Sharing: Not stated. Countries: 0. Publications: 5.

Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks

ClinicalTrials.gov study NCT02051218. IPD Sharing: Not stated. Countries: 3. Publications: 1.

The Effect of Denosumab on Muscle and Strength and Insulin Sensitivity

ClinicalTrials.gov study NCT07271771. IPD Sharing: NO. Countries: 1. Publications: 15.

Alendronate Versus Denosumab in Kidney Transplant Patients

ClinicalTrials.gov study NCT04169698. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.

Study Evaluating Denosumab on Bone and Vascular Metabolism in Osteoporotic Chronic Kidney Disease

ClinicalTrials.gov study NCT02792413. IPD Sharing: NO. Countries: 1. Publications: 1.

Denosumab Sequential Therapy

ClinicalTrials.gov study NCT03868033. IPD Sharing: NO. Countries: 1. Publications: 2.

Study to Evaluate the Safety and Efficacy of Denosumab and Actonel® in Post Menopausal Women Transitioned From Alendronate Therapy

ClinicalTrials.gov study NCT00919711. IPD Sharing: Not stated. Countries: 0. Publications: 2.

Characteristics and Mechanism of Denosumab-treated Giant Cell Tumor of Bone

ClinicalTrials.gov study NCT03259152. IPD Sharing: NO. Countries: 1. Publications: 3.